Limits...
Dengue Vaccines: A Perspective from the Point of View of Intellectual Property.

da Veiga CP, da Veiga CR, Del Corso JM, da Silva WV - Int J Environ Res Public Health (2015)

Bottom Line: The results show that 93% of patents were granted since 2000, the majority belonging to the United States and Europe, although the share of patents from developing countries has increased.Finally, in this study, the main holders showed high knowledge absorption and generated capabilities.Therefore, this issue suggests that to overcome the difficulty of translational R & D it is necessary to stimulate the generation of knowledge and relevant scientific research, to enable the productive sector to have the capacity to absorb knowledge, to turn it into innovation, and to articulate partnerships and collaboration.

View Article: PubMed Central - PubMed

Affiliation: Pontifical Catholic University of Paraná, PUCPR, Rua Imaculada Conceição, 1155 Prado Velho, 80215-901 Curitiba, PR, Brazil. claudimar.veiga@gmail.com.

ABSTRACT
Dengue is a serious infectious disease and a growing public health problem in many tropical and sub-tropical countries. To control this neglected tropical disease (NTD), vaccines are likely to be the most cost-effective solution. This study analyzed dengue vaccines from both a historical and longitudinal perspective by using patent data, evaluating the geographic and time coverage of innovations, the primary patent holders, the network of cooperation and partnership for vaccine research and development (R & D), the flow of knowledge and the technological domain involved. This study can be seen as an example of the use of patent information to inform policy discussions, strategic research planning, and technology transfer. The results show that 93% of patents were granted since 2000, the majority belonging to the United States and Europe, although the share of patents from developing countries has increased. Unlike another NTDs, there is great participation of private companies in R & D of dengue vaccines and partnerships and collaboration between public and private companies. Finally, in this study, the main holders showed high knowledge absorption and generated capabilities. Therefore, this issue suggests that to overcome the difficulty of translational R & D it is necessary to stimulate the generation of knowledge and relevant scientific research, to enable the productive sector to have the capacity to absorb knowledge, to turn it into innovation, and to articulate partnerships and collaboration.

No MeSH data available.


Related in: MedlinePlus

Distribution of search results by main co-ownerships of late-stage dengue vaccine developers. Part A: co-ownership of Takeda; Part B: co-ownership of US National Institute of Health; Part C: co-ownership of US Army; Part D: co-ownership of Sanofi Pasteur.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4555291&req=5

ijerph-12-09454-f005: Distribution of search results by main co-ownerships of late-stage dengue vaccine developers. Part A: co-ownership of Takeda; Part B: co-ownership of US National Institute of Health; Part C: co-ownership of US Army; Part D: co-ownership of Sanofi Pasteur.

Mentions: Figure 5 presents the distribution of search results by co-ownership only of late-stage dengue vaccine developers [25]. Network node sizes are displayed in proportion to their “convergence points”, an indicator of the gatekeeper/broker role of the node in the network. In Figure 5 (Part A), it is possible to examine the relationship between the two private pharmaceutical companies Takeda and Inviragen. These private companies jointly announced in 2013 that they have entered into a definitive agreement for Takeda to acquire Inviragen. This acquisition combines Inviragen’s expertise in both viral vaccine P & D and extensive worldwide network of preclinical and clinical collaborators with Takeda’s resources, product development expertise, and global reach [29]. Figure 5 (Part A) also illustrates that Takeda has worked with the US Government and its product, a live attenuated tetravalent recombinant chimeric vaccine candidate using an attenuated DENV-2 backbone, is currently in phase II clinical development [25].


Dengue Vaccines: A Perspective from the Point of View of Intellectual Property.

da Veiga CP, da Veiga CR, Del Corso JM, da Silva WV - Int J Environ Res Public Health (2015)

Distribution of search results by main co-ownerships of late-stage dengue vaccine developers. Part A: co-ownership of Takeda; Part B: co-ownership of US National Institute of Health; Part C: co-ownership of US Army; Part D: co-ownership of Sanofi Pasteur.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4555291&req=5

ijerph-12-09454-f005: Distribution of search results by main co-ownerships of late-stage dengue vaccine developers. Part A: co-ownership of Takeda; Part B: co-ownership of US National Institute of Health; Part C: co-ownership of US Army; Part D: co-ownership of Sanofi Pasteur.
Mentions: Figure 5 presents the distribution of search results by co-ownership only of late-stage dengue vaccine developers [25]. Network node sizes are displayed in proportion to their “convergence points”, an indicator of the gatekeeper/broker role of the node in the network. In Figure 5 (Part A), it is possible to examine the relationship between the two private pharmaceutical companies Takeda and Inviragen. These private companies jointly announced in 2013 that they have entered into a definitive agreement for Takeda to acquire Inviragen. This acquisition combines Inviragen’s expertise in both viral vaccine P & D and extensive worldwide network of preclinical and clinical collaborators with Takeda’s resources, product development expertise, and global reach [29]. Figure 5 (Part A) also illustrates that Takeda has worked with the US Government and its product, a live attenuated tetravalent recombinant chimeric vaccine candidate using an attenuated DENV-2 backbone, is currently in phase II clinical development [25].

Bottom Line: The results show that 93% of patents were granted since 2000, the majority belonging to the United States and Europe, although the share of patents from developing countries has increased.Finally, in this study, the main holders showed high knowledge absorption and generated capabilities.Therefore, this issue suggests that to overcome the difficulty of translational R & D it is necessary to stimulate the generation of knowledge and relevant scientific research, to enable the productive sector to have the capacity to absorb knowledge, to turn it into innovation, and to articulate partnerships and collaboration.

View Article: PubMed Central - PubMed

Affiliation: Pontifical Catholic University of Paraná, PUCPR, Rua Imaculada Conceição, 1155 Prado Velho, 80215-901 Curitiba, PR, Brazil. claudimar.veiga@gmail.com.

ABSTRACT
Dengue is a serious infectious disease and a growing public health problem in many tropical and sub-tropical countries. To control this neglected tropical disease (NTD), vaccines are likely to be the most cost-effective solution. This study analyzed dengue vaccines from both a historical and longitudinal perspective by using patent data, evaluating the geographic and time coverage of innovations, the primary patent holders, the network of cooperation and partnership for vaccine research and development (R & D), the flow of knowledge and the technological domain involved. This study can be seen as an example of the use of patent information to inform policy discussions, strategic research planning, and technology transfer. The results show that 93% of patents were granted since 2000, the majority belonging to the United States and Europe, although the share of patents from developing countries has increased. Unlike another NTDs, there is great participation of private companies in R & D of dengue vaccines and partnerships and collaboration between public and private companies. Finally, in this study, the main holders showed high knowledge absorption and generated capabilities. Therefore, this issue suggests that to overcome the difficulty of translational R & D it is necessary to stimulate the generation of knowledge and relevant scientific research, to enable the productive sector to have the capacity to absorb knowledge, to turn it into innovation, and to articulate partnerships and collaboration.

No MeSH data available.


Related in: MedlinePlus